Titel

Merkliste
1 Ergebnisse

Development of Alectinib-Based PROTACs as Novel Potent Degr..:

Shaowen Xie (6437030) ; Yuan Sun (15554) ; Yulin Liu (457083)...
https://figshare.com/articles/journal_contribution/Development_of_Alectinib-Based_PROTACs_as_Novel_Potent_Degraders_of_Anaplastic_Lymphoma_Kinase_ALK_/14864966. , 2021

Link: https://doi.org/10.1021/acs.jmedchem.1c00270.s001

RT Journal
T1 <Title>Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftsmithonian:oai:figshare.com:article_14864966&Exemplar=1&LAN=DE
				
A1 Shaowen Xie (6437030)
A1 Yuan Sun (15554)
A1 Yulin Liu (457083)
A1 Xinnan Li (3317892)
A1 Xinuo Li (10860388)
A1 Wenyi Zhong (11035337)
A1 Feiyan Zhan (11035340)
A1 Jingjie Zhu (11035343)
A1 Hong Yao (348216)
A1 Dong-Hua Yang (223092)
A1 Zhe-Sheng Chen (223107)
A1 Jinyi Xu (1748593)
A1 Shengtao Xu (513564)
YR 2021
K1 Biochemistry
K1 Medicine
K1 Cell Biology
K1 Genetics
K1 Pharmacology
K1 Biotechnology
K1 Cancer
K1 Infectious Diseases
K1 Environmental Sciences not elsewhere classified
K1 Biological Sciences not elsewhere classified
K1 Chemical Sciences not elsewhere classified
K1 I.V
K1 degrader
K1 ALK-dependent cell lines
K1 P.O
K1 Karpas 299 xenograft mouse model
K1 tumor weight
K1 Anaplastic Lymphoma Kinase
K1 PROTAC
K1 alectinib
K1 mg
K1 Novel Potent Degraders
K1 compound 17
K1 ALK-sustained degradation ability
K1 ALK fusion-negative cells
K1 novel anaplastic lymphoma kinase
JF https://figshare.com/articles/journal_contribution/Development_of_Alectinib-Based_PROTACs_as_Novel_Potent_Degraders_of_Anaplastic_Lymphoma_Kinase_ALK_/14864966
LK http://dx.doi.org/https://doi.org/10.1021/acs.jmedchem.1c00270.s001
DO https://doi.org/10.1021/acs.jmedchem.1c00270.s001
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)